|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
In 1H17, Novartis's (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.
In 1H17, Teva Pharmaceutical's (TEVA) Copaxone reported revenues of ~$2.1 billion, or ~7% lower YoY (year-over-year).
Merck's (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.